The Effectiveness and Safety Analysis of Duloxetine in Treating Comorbid Depression in Parkinson's Disease: A Retrospective Study

• Zhuoqun Wang ^[1] ; Jing Tian ^[1] ; Weixin Dai ^[2] ; Na Zhang ^[3] ; Jianglin Wang ^[4] ; Zhanyu Li ^[5]
  1. [1] Department of Neurology, Jilin Province FAW General Hospital, Changchun, Jilin, China
  2. [2] Department of Cardiology, Jilin Province FAW General Hospital, Changchun, Jilin, China
  3. [3] Department of Electrodiagnosis, Jilin Province FAW General Hospital, Changchun, Jilin, China
  4. [4] Department of Psychiatry, Yanbian Brain Hospital, Yanji, Jilin, China
  5. [5] Department of Traumatology, Jilin Province FAW General Hospital, Changchun, Jilin, China

  Mostrar afiliaciones +
• Localización: Actas españolas de psiquiatría, ISSN 1139-9287, Vol. 52, Nº. 5, 2024, págs. 607-615
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background: Parkinson's disease (PD) is a neurodegenerative disorder characterized by both motor and non-motor symptoms, including depression, which significantly impacts the quality of life of affected individuals. This study aims to investigate the real-world effectiveness and safety of duloxetine in treating comorbid depression in patients with Parkinson's disease and to compare its outcomes with traditional treatment approaches.

    Methods: This study included adult patients diagnosed with Parkinson's disease combined with depression from December 2020 to December 2023. Based on the use of duloxetine, the cohort was divided into a traditional treatment group and a duloxetine group (traditional treatment combined with duloxetine). Patients with incomplete medical records, concurrent antidepressant therapy, or major psychiatric or neurological disorders were excluded. Retrospective data, including demographic information, treatment adherence, and various assessment scores, were collected from medical records by trained research staff.

    Results: In total, 106 patients were analyzed, with 50 patients receiving traditional treatment and 56 patients receiving duloxetine. The duloxetine group exhibited significantly lower scores than the traditional treatment group in the Unified PD Rating Scale (p = 0.015), Hamilton Depression Rating Scale (p = 0.013), Beck Depression Inventory (p = 0.031), Parkinson's disease Questionnaire-39 (p = 0.006), and Clinical Global Impression-Improvement (p < 0.001) scores. In motor function assessment, the duloxetine group demonstrated improvements in kinetic tremor scores (p = 0.017), gait speed (p < 0.001), Timed Up and Go Test performance (p < 0.001), dyskinesia severity (p = 0.017), and rigidity (p = 0.019) compared to the traditional treatment group. Additionally, the duloxetine group exhibited better cognitive function across various assessments, including the Symbol Digit Modalities Test (p = 0.024), Stroop Color-Word Test (p = 0.048), and Montreal Cognitive Assessment (p = 0.024).

    Conclusion: Duloxetine is associated with superior efficacy in improving motor and non-motor symptoms, overall clinical status, and cognitive function. These findings support the potential utility of duloxetine as a comprehensive treatment option for comorbid depression in Parkinson's disease.